My firm invested in a bio company and we are disappointed with the poor performance of the share price yet many pharmaceutical/biotech companies have done well in this covid-19 environment.
We are of the view that the company should consider what other small bio firms have done ie re-purposing their existing projects for therapeutics to help with Covid-19 or simply putting out an announcement out in the market to know that if there are any potential partners whether industrial, governmental or academic, out there that have complementary resource and expertise wishing to explore the company’s existing projects with the effort of combating Covid to contact the company.
I’m not a pharmaceutical/bio person and just wanted some views on the company’s products to see if there is any argument there before i approach the board: https://www.valirx.com/about-us/products-technology/
Any thoughts?